Assessment of Beta-AR protein expression on tumour tissues might be a plausible strategy to select cancer patients who can benefit from Beta-blockers therapy. The aim of this study is to evaluate the differences between resected tissue specimens from primary lung cancer (adenocarcinoma (ADC) and squamous cell carcinoma (SCC)) in terms of expression pattern of Beta1- and Beta2-AR in both tumour and adjacent surrounding non-tumour tissue. This retrospective study was based on the analysis of 80 patients with histologically confirmed diagnosis of primary Non-Small Cell Lung Cancer (NSCLC) who received surgical treatment. The cases were carefully selected in order to obtain the most homogeneous sample in terms of histologic subtype (40 ADCs and 40 SCCs) and clinical stage (10 each). Beta1- and Beta2-AR expression was determined by immunohistochemistry and the staining evaluated by semi-quantitative scoring using the H-score method. In our NSCLC series, Beta1- and Beta2-AR are differentially expressed. Beta1-AR expression is present at low levels in both SCC and ADC. Likewise, when compared with the matched surrounding non-tumour tissues, Beta1-AR expression level was significantly lower in both histologic subtypes. Conversely, Beta2-AR is highly expressed in both histologic subtypes, but clearly highly expressed in ADC when compared with SCC and with their matched surrounding non-tumour tissue. Overall, this clinicopathological study highlights the differential expression of Beta1- and Beta2-AR in ADC and SCC. Repurposing non-selective Beta-blockers in oncologic setting might be a suitable therapeutic strategy for lung ADC.

Graphical abstract

中文翻译：

---

人非小细胞肺癌中的β1和β2肾上腺素受体表达模式：与癌症组织学的关系。

评估肿瘤组织上β-AR蛋白的表达可能是选择可以从β受体阻滞剂治疗中受益的癌症患者的可行策略。这项研究的目的是评估从原发性肺癌（腺癌（ADC）和鳞状细胞癌（SCC））中切除的组织标本在肿瘤和邻近周围非癌组织中β1-和β2-AR的表达方式上的差异。 -肿瘤组织。这项回顾性研究基于对经手术治疗的80例经组织学确诊为原发性非小细胞肺癌（NSCLC）的患者的分析。仔细选择病例，以获得组织学亚型（40个ADC和40个SCC）和临床分期（每个10个）最均匀的样本。通过免疫组织化学确定β1-和β2-AR的表达，并使用H分数法通过半定量评分评估染色。在我们的NSCLC系列中，Beta1-和Beta2-AR差异表达。Beta1-AR表达在SCC和ADC中均处于较低水平。同样，与匹配的周围非肿瘤组织相比，两种组织学亚型中的Beta1-AR表达水平均显着降低。相反，Beta2-AR在两种组织学亚型中均高表达，但与SCC及其匹配的周围非肿瘤组织相比，在ADC中明显高表达。总的来说，这项临床病理研究突出了ADC和SCC中Beta1-和Beta2-AR的差异表达。在肿瘤环境中重新使用非选择性Beta受体阻滞剂可能是肺ADC的合适治疗策略。Beta1-和Beta2-AR差异表达。Beta1-AR表达在SCC和ADC中均处于较低水平。同样，与匹配的周围非肿瘤组织相比，两种组织学亚型中的Beta1-AR表达水平均显着降低。相反，Beta2-AR在两种组织学亚型中均高表达，但与SCC及其匹配的周围非肿瘤组织相比，在ADC中明显高表达。总的来说，这项临床病理研究突出了ADC和SCC中Beta1-和Beta2-AR的差异表达。在肿瘤环境中重新使用非选择性Beta受体阻滞剂可能是肺ADC的合适治疗策略。Beta1-和Beta2-AR差异表达。Beta1-AR表达在SCC和ADC中均处于较低水平。同样，与匹配的周围非肿瘤组织相比，两种组织学亚型中的Beta1-AR表达水平均显着降低。相反，Beta2-AR在两种组织学亚型中均高表达，但与SCC及其匹配的周围非肿瘤组织相比，在ADC中明显高表达。总的来说，这项临床病理研究突出了ADC和SCC中Beta1-和Beta2-AR的差异表达。在肿瘤环境中重新使用非选择性Beta受体阻滞剂可能是肺ADC的合适治疗策略。在两种组织学亚型中，β1-AR表达水平均显着降低。相反，Beta2-AR在两种组织学亚型中均高表达，但与SCC及其匹配的周围非肿瘤组织相比，在ADC中明显高表达。总的来说，这项临床病理研究突出了ADC和SCC中Beta1-和Beta2-AR的差异表达。在肿瘤环境中重新使用非选择性Beta受体阻滞剂可能是肺ADC的合适治疗策略。在两种组织学亚型中，β1-AR表达水平均显着降低。相反，Beta2-AR在两种组织学亚型中均高表达，但与SCC及其匹配的周围非肿瘤组织相比，在ADC中明显高表达。总的来说，这项临床病理研究突出了ADC和SCC中Beta1-和Beta2-AR的差异表达。在肿瘤环境中重新使用非选择性Beta受体阻滞剂可能是肺ADC的合适治疗策略。

图形概要